02257.HK
Sirnaomics Ltd.
HKSE · Healthcare · Biotechnology · HK
HKD 4.13
+0.00%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +18.1%
- EBIT
- +25.8%
- EPS
- +35.6%
- Free cash flow
- +1.7%
- Operating cash flow
- +1.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +55.2%
- EBIT
- +58.2%
- Net income
- +71.9%
- EPS
- +77.3%
- Free cash flow
- +53.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026